Research programme: type 2 diabetes mellitus biotherapeutics - Precigen Inc/Janssen Pharmaceutica
Latest Information Update: 11 Feb 2020
At a glance
- Originator Intrexon Corporation; Janssen Pharmaceutica
- Developer Janssen Pharmaceutica; Precigen Inc
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Metabolic disorders; Obesity; Type 2 diabetes mellitus
Most Recent Events
- 03 Feb 2020 Intrexon Corporation is now called Precigen Inc
- 28 Jan 2020 No recent reports of development identified for research development in Metabolic-disorders in USA (PO)
- 28 Jan 2020 No recent reports of development identified for research development in Obesity in USA (PO)
Development Overview
Introduction
Precigen Inc (formerly Intrexon Corporation) and Janssen Pharmaceutica are collaboratively developing oral biotherapeutics using Intrexon's proprietary ActoBiotics® platform for the treatment and prevention of type 2 diabetes mellitus. These therapeutics will be directed against selected targets to treat type 2 diabetes mellitus, obesity and/or metabolic disorders related to energy dysregulation. Further, ActoBiotics® platform will be utilised to express certain effectors for the prevention of disease progression to full-stage in pre-diabetics.
ActoBiotics® platform engineers food-grade microbes like Lactococcus lactis to generate biotherapeutics for in situ expression and secretion of novel proteins and peptides including cytokines, enzymes, hormones, and monoclonal antibodies within the body and enables selective delivery of biological effectors to the oral and gastrointestinal tract. ActoBiotics® have the potential to improve efficacy in maintaining glycaemic control in the long term.
Precigen Inc is also conducting its own research programme for type 2 diabetes mellitus biotherapeutics [see RDI Profile 800039572]
As at January 2020, no recent reports of development had been identified for research development in Metabolic-disorders in USA (PO), research development in Obesity in USA (PO), research development in Type-2-diabetes-mellitus in USA (PO), research development in Type-2-diabetes-mellitus (Prevention) in USA (PO).
In February 2020, Intrexon Corporation has changed its name to Precigen Inc [1] .
Company Agreements
In December 2015, Intrexon and Janssen Pharmaceutica entered into a research collaboration for the discovery and development of ActoBiotics® biotherapeutics for the treatment and prevention of type 2 diabetes mellitus. The deal was facilitated by Johnson and Johnson Innovation [2] .
Drug Properties & Chemical Synopsis
- Route of administration PO
- Formulation unspecified
- Mechanism of Action Undefined mechanism
-
WHO ATC code
A08A-X (Other antiobesity drugs)
A10X (Other Drugs Used in Diabetes)
A16A (Other Alimentary Tract and Metabolism Products)
-
EPhMRA code
A10X9 (Other drugs used in diabetes)
A16A (Other Alimentary Tract and Metabolism Products)
A8 (Antiobesity Preparations, Excluding Dietetics)
Development Status
Summary Table
| Indication | Qualifier | Patient Segment | Phase | Countries | Route / Formulation | Developers | Event Date |
|---|---|---|---|---|---|---|---|
| Metabolic disorders | - | - | No development reported (Research) | USA | PO / unspecified | Janssen Pharmaceutica, Precigen Inc | 28 Jan 2020 |
| Obesity | - | - | No development reported (Research) | USA | PO / unspecified | Janssen Pharmaceutica, Precigen Inc | 28 Jan 2020 |
| Type 2 diabetes mellitus | - | Prevention | No development reported (Research) | USA | PO / unspecified | Janssen Pharmaceutica, Precigen Inc | 28 Jan 2020 |
| Type 2 diabetes mellitus | - | - | No development reported (Research) | USA | PO / unspecified | Janssen Pharmaceutica, Precigen Inc | 28 Jan 2020 |
Commercial Information
Involved Organisations
| Organisation | Involvement | Countries |
|---|---|---|
| Janssen Pharmaceutica | Originator | Belgium |
| Intrexon Corporation | Originator | USA |
| Precigen Inc | Owner | USA |
Development History
| Event Date | Update Type | Comment |
|---|---|---|
| 03 Feb 2020 | Company Involvement | Intrexon Corporation is now called Precigen Inc Updated 11 Feb 2020 |
| 28 Jan 2020 | Phase Change - No development reported | No recent reports of development identified for research development in Metabolic-disorders in USA (PO) Updated 28 Jan 2020 |
| 28 Jan 2020 | Phase Change - No development reported | No recent reports of development identified for research development in Obesity in USA (PO) Updated 28 Jan 2020 |
| 28 Jan 2020 | Phase Change - No development reported | No recent reports of development identified for research development in Type-2-diabetes-mellitus in USA (PO) Updated 28 Jan 2020 |
| 28 Jan 2020 | Phase Change - No development reported | No recent reports of development identified for research development in Type-2-diabetes-mellitus(Prevention) in USA (PO) Updated 28 Jan 2020 |
| 22 Dec 2015 | Licensing Status | Intrexon and Janssen Pharmaceutica agree to co-develop oral biotherapeutics for Type-2 diabetes mellitus (treatment and prevention) [2] Updated 29 Dec 2015 |
| 22 Dec 2015 | Phase Change | Early research in Metabolic disorders in USA (PO) Updated 29 Dec 2015 |
| 22 Dec 2015 | Phase Change | Early research in Obesity in USA (PO) Updated 29 Dec 2015 |
| 22 Dec 2015 | Phase Change | Early research in Type-2 diabetes mellitus in USA (PO) Updated 29 Dec 2015 |
| 22 Dec 2015 | Phase Change | Early research in Type-2-diabetes mellitus prevention in USA (PO) Updated 29 Dec 2015 |
References
-
Precigen Completes Series Of Transactions To Solidify Healthcare Focus.
Media Release -
Intrexon Announces a Collaboration with Johnson & Johnson Innovation for Type 2 Diabetes Therapies.
Media Release
Adis International Ltd. Part of Springer Science+Business Media
© Springer Nature Switzerland AG